Health
Inflammation marker linked to increased fatigue in prostate cancer patients treated with ADT – News-Medical.Net
Prostate cancer is one of the most common cancers among men in the U.S. For many patients, hormone therapy is a treatment option.
Prostate cancer is one of the most common cancers among men in the U.S. For many patients, hormone therapy is a treatment option. This type of therapy, also called androgen deprivation therapy (ADT), reduces the level of testosterone and other androgens in the body. Lowering androgen levels can make prostate cancer cells grow more slowly or shrink tumors over time. However, patients receiving ADT often experience higher levels of fatigue, depression and cognitive impairment.
Moffitt Cancer Center…
-
Noosa News19 hours agoSuncorp Stadium upgrades to rival Sydney as seat capacity and infrastructure prioritised
-
Business23 hours agoWhy you should sell CBA, Lynas, and Tabcorp shares today
-
General13 hours agoAustralia Kangaroos lose Xavier Coates and Zac Lomax ahead of rugby league Ashes in England
-
Business21 hours agoDroneShield announces new $13 million counter-drone facility as employees top 400